Predict your next investment

Venture Capital
polarisfc.com

See what CB Insights has to offer

Investments

4

Portfolio Exits

3

About Polaris Founders Capital

Polaris Founders Capital makes substantial investments in fast-growing companies in the US and abroad. PFC makes minority and control investments to support growth as well as to provide founders liquidity.

Polaris Founders Capital Headquarter Location

Boston, Massachusetts,

United States

781-399-5860

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Polaris Founders Capital News

Amylyx Pharmaceuticals Raises $135M in Series C Financing

Jul 20, 2021

Amylyx Pharmaceuticals, Inc. , a Cambridge, MA-based pharmaceutical company, closed $135m in Series C financing. The round was led by Viking Global Investors, with participation from Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund and Falcon Edge, as well as existing investors Morningside Ventures, 683 Capital Management, Belinda Termeer and Polaris Founders Capital. The company intends to use the funds for the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. AMX0035 is an investigational product comprised of two complementary active agents, sodium phenylbutyrate (PB) and taurursodiol (TURSO; also known as ursodoxicoltaurine), which were combined in a co-formulation to reduce neuronal death and dysfunction. AMX0035 was specifically co-formulated and manufactured by Amylyx to ensure proper absorption, exposure, and quality. AMX0035 targets endoplasmic reticulum and mitochondrial-dependent neuronal degeneration pathways in ALS and other neurodegenerative diseases. FinSMEs 20/07/2021

Polaris Founders Capital Investments

4 Investments

Polaris Founders Capital has made 4 investments. Their latest investment was in Amylyx Pharmaceuticals as part of their Series C on July 7, 2021.

CBI Logo

Polaris Founders Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/20/2021

Series C

Amylyx Pharmaceuticals

$135M

Yes

11

3/3/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

7/23/2019

Series C

Subscribe to see more

$99M

Subscribe to see more

10

1/7/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/20/2021

3/3/2020

7/23/2019

1/7/2019

Round

Series C

Series B

Series C

Series B

Company

Amylyx Pharmaceuticals

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$135M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

11

10

10

10

Polaris Founders Capital Portfolio Exits

3 Portfolio Exits

Polaris Founders Capital has 3 portfolio exits. Their latest portfolio exit was Amylyx Pharmaceuticals on January 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/7/2022

IPO

$99M

Public

6

6/26/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/3/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/7/2022

6/26/2020

10/3/2019

Exit

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

6

10

10

Polaris Founders Capital Team

2 Team Members

Polaris Founders Capital has 2 team members, including current Founding Partner, Jonathan A. Flint.

Name

Work History

Title

Status

Jonathan A. Flint

Founding Partner

Current

Gregg Rubin

General Partner

Current

Name

Jonathan A. Flint

Gregg Rubin

Work History

Title

Founding Partner

General Partner

Status

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.